Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus estramustine plus prednisone vs docetaxel plus prednisone in advanced prostate cancer with biochemical relapse
2004-003885-14Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in prostate adenocarcinoma (2 arms), sponsored by Sanofi. Primary endpoint: PSA response rates. Started Jan 2006; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2004-003885-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003885-14.